Product Development Advisory Committee
The Product Development Advisory Committee (PDAC) provides expertise to the Oversight Committee on the growing gap between translational discovery and later stage clinical development of new oncology drugs in Texas. Primarily, it is making recommendations on the breadth of life science expertise needed in Texas to advance the state’s ability to improve cancer patient outcomes from promising scientific discoveries.
Related Documents:
Product Development Advisory Committee Annual Report for Fiscal Year 2025Product Development Advisory Committee Annual Report for Fiscal Year 2024
|
Andrew Strong, JD, Chair Partner, Hogan Lovells, LLP
Founding CEO & President, Kalon Biotherapeutics
|
|
Michele Park, Ph.D., Vice-Chair Partner
NEA
|
|
Claire Aldridge, Ph.D. Chief of Staff and SVP, Business Operations
Taysha Gene Therapies
|
|
David Arthur CEO
Salarius Pharmaceuticals
|
|
Bruce Butler, Ph.D. Vice President, Research and Technology
Director, Office of Technology Management
UT Health Sciences Center at Houston
|
|
Gabby Everett, Ph.D. Site Director
BioLabs Pegasus Park
|
|
Victoria Ford President and CEO
Texas Healthcare & Bioscience Institute
|
|
Julie Goonewardene Associate Vice Chancellor for Innovation and Strategic Investment
The University of Texas System
|
|
Heather Hanson President
BioMedSA
|
|
Dan Hargrove, JD, LLM Founder
Texas BioTech Ventures, LLC
|
|
Paul Lammers, M.D. CEO, President and Director, Triumvira Immunologics
Former CEO and President, Mirna Therapeutics
|
|
David Lowe, Ph.D. Co-Founder, Aeglea Biotherapeutics
Managing Director, AllosteRx Capital
|
|
Tom Luby, Ph.D. Director
Texas Medical Center (TMC) Innovation
|
|
Jonathan MacQuitty, Ph.D. Venture Partner
Lightspeed Venture Partners
|
|
Dennis McWilliams Venture Partner
Sante Ventures
|
|
Jon Mogford, Ph.D. Chief Operating Officer and Senior Vice President
Texas A&M University Health Science Center
|
|
Emily Reiser, Ph.D. Associate Director
Texas Medical Center Innovation
|
|
Emma Schwartz Managing Partner
Ecotone Investment Fund
|
|
Greg Stein, M.D. CEO
Curtana Pharmaceuticals
|
|
Ann Tanabe CEO
BioHouston, Inc.
|